Genomic Expression, Inc.
Genomic Expression Inc is pioneering a next-generation RNA AI platform that enables personalized cancer treatment and drug discovery. Their OneRNA® platform analyzes all 20,000+ mRNAs in a patient's sample to identify the most effective treatments, offering a highly diagnostic yield and the potential to make cancer a treatable disease. The company is focused on individualizing cancer therapy, developing RNA therapeutics, and improving healthcare outcomes through advanced genomic analysis and AI-driven algorithms.
Industries
Nr. of Employees
small (1-50)
Genomic Expression, Inc.
100 Cummings Center, Suite 451C, Beverly, MA 01915
Products
Comprehensive RNA analysis and clinical report
A clinical-grade assay and interpretive report that quantifies the tumor mRNA transcriptome and prioritizes approved drugs and relevant clinical trials for individual patients; intended to support treatment navigation.
Comprehensive RNA analysis and clinical report
A clinical-grade assay and interpretive report that quantifies the tumor mRNA transcriptome and prioritizes approved drugs and relevant clinical trials for individual patients; intended to support treatment navigation.
Services
End-to-end clinical sequencing of tumor tissue with interpretation that maps quantitative mRNA expression to potential approved therapies and clinical trials; reports delivered to treating clinicians.
Consulting and execution support for drug developers to use comprehensive RNA profiles to derisk and accelerate clinical trials, develop algorithmic companion diagnostics, and define enrollment strategies (basket/umbrella studies).
Research and translational support to convert RNA expression signatures into designed RNA-based therapeutic constructs and envision rapid manufacture of individualized RNA therapeutics.
End-to-end clinical sequencing of tumor tissue with interpretation that maps quantitative mRNA expression to potential approved therapies and clinical trials; reports delivered to treating clinicians.
Consulting and execution support for drug developers to use comprehensive RNA profiles to derisk and accelerate clinical trials, develop algorithmic companion diagnostics, and define enrollment strategies (basket/umbrella studies).
Research and translational support to convert RNA expression signatures into designed RNA-based therapeutic constructs and envision rapid manufacture of individualized RNA therapeutics.
Expertise Areas
- RNA sequencing-based diagnostics
- AI-driven treatment selection
- Drug repurposing for oncology
- Companion diagnostic algorithm development
Key Technologies
- Next-generation RNA sequencing (RNA-seq)
- FFPE-compatible RNA sample preparation
- AI / machine-learning diagnostic algorithms
- Drug–RNA expression mapping databases
News & Updates
Presenting at the New York Stock Exchange
The company is scheduled to present at the NYSE, highlighting its innovative RNA platform.
In-network with major payors including Medicare
The company's tests are reimbursed at $3,000 per test, with broad insurance coverage.
Potential $3.5M NCI contract under consideration
The company is in discussions for a significant research contract with the National Cancer Institute.
Supported by major grants and investors
Supported by grants from Genome Denmark, Hojteknologi Fonden, and investors including Harvard Business Angels.
Awards and recognitions
Winner of the Lyfebulb-Helsinn Award, EIC Lifescience Award, and featured in Forbes.
Algorithms are already used today in cancer treatment selection, but improvements are needed for better individualization. Genomic Expression has developed validated RNA-based algorithms for personalized treatment.
Presenting at the New York Stock Exchange
The company is scheduled to present at the NYSE, highlighting its innovative RNA platform.
In-network with major payors including Medicare
The company's tests are reimbursed at $3,000 per test, with broad insurance coverage.
Potential $3.5M NCI contract under consideration
The company is in discussions for a significant research contract with the National Cancer Institute.
Supported by major grants and investors
Supported by grants from Genome Denmark, Hojteknologi Fonden, and investors including Harvard Business Angels.
Awards and recognitions
Winner of the Lyfebulb-Helsinn Award, EIC Lifescience Award, and featured in Forbes.
Algorithms are already used today in cancer treatment selection, but improvements are needed for better individualization. Genomic Expression has developed validated RNA-based algorithms for personalized treatment.